Association between polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln genes and prognosis of colorectal cancer in a Chinese population
| Autor: | Yi Gan, Dao-Jin Chen, Jun-Hui Wu, Xiao-Rong Li |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Genotype Organoplatinum Compounds Epidemiology Colorectal cancer medicine.medical_treatment Lower risk Gastroenterology Polymerase Chain Reaction XRCC1 Asian People Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Survival rate Genotyping Neoplasm Staging Xeroderma Pigmentosum Group D Protein Chemotherapy Polymorphism Genetic business.industry Public Health Environmental and Occupational Health Middle Aged medicine.disease Prognosis Oxaliplatin DNA-Binding Proteins Survival Rate X-ray Repair Cross Complementing Protein 1 Oncology Cancer research Female Fluorouracil business Colorectal Neoplasms Polymorphism Restriction Fragment Length medicine.drug Follow-Up Studies |
| Zdroj: | Asian Pacific journal of cancer prevention : APJCP. 13(11) |
| ISSN: | 2476-762X |
| Popis: | We conducted this study to detect associations between XRCC1 Arg399Gln and XPD Lys751Gln genotypes and survival of colorectal cancer patients treated with 5-FU/oxalipatin chemotherapy. We included 289 Chinese patients with advanced colorectal cancer, who had received 5-FU/oxalipatin chemotherapy as first-line treatment from January 2005 to January 2007. All patients were followed up till Nov. 2011. Genotyping for XRCC1 Arg399Gln and XPD Lys751Gln polymorphisms was based upon duplex polymerase-chain-reaction with the PCR-RFLP method. In our study, we found the XRCC1 399 Gln/Gln genotype to confer significantly higher rates of response to chemotherapy when compared to the Arg/Arg genotype [OR (95% CI)= 2.56(1.57-2.55)]. patients with the XPD 751 Gln/Gln genotype had significantly higher rates of response to chemotherapy [OR (95% CI)= 1.54(0.87-2.65)] and those with the XRCC1 399 Gln/Gln genotype had a longer average survival time and significantly lower risk of death than did those with the Arg/Arg genotype [HR (95% CI)= 0.66(0.360.95)]. Similarly, those carrying the XPD 751Gln/Gln genotype had 0.51-fold the risk of death of those with XPD 751Lys/Lys [HR (95% CI)= 0.51(0.33 -0.94)]. In conclusion, it is suggested that the XRCC1 Arg399Gln and XPD Lys751Gln polymorphisms should be routinely assessed to determine colorectal patients who are more likely to benefit from 5-FU/oxalipatin chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|